

1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) are responsible for the management and supervision of the Company's business operations, respectively. The Board is composed of the Chairman of the Board, the President, and the Directors. The Supervisory Committee is composed of the Chairman of the Supervisory Committee and the Supervisors. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively.
2. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively. The Board is composed of the Chairman of the Board, the President, and the Directors. The Supervisory Committee is composed of the Chairman of the Supervisory Committee and the Supervisors. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively.
3. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively. The Board is composed of the Chairman of the Board, the President, and the Directors. The Supervisory Committee is composed of the Chairman of the Supervisory Committee and the Supervisors. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively.
4. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively. The Board is composed of the Chairman of the Board, the President, and the Directors. The Supervisory Committee is composed of the Chairman of the Supervisory Committee and the Supervisors. The Board and the Supervisory Committee are responsible for the management and supervision of the Company's business operations, respectively.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

1. 2021年3月31日

2021年3月31日

	31 March 2021	31 December 2020	Ratio of change (%)
总资产	1,123,456,789	1,098,765,432	1.4%
流动资产	456,789,123	445,678,912	2.5%
非流动资产	666,667,666	653,086,520	1.9%
总负债	567,890,123	556,789,012	1.8%
流动负债	234,567,890	223,456,789	5.0%
非流动负债	333,322,233	333,332,223	0.0%
所有者权益	555,566,666	542,076,420	2.5%
实收资本	100,000,000	100,000,000	0.0%
资本公积	150,000,000	150,000,000	0.0%
盈余公积	100,000,000	100,000,000	0.0%
未分配利润	205,566,666	192,076,420	6.5%
少数股东权益	0	0	0.0%
归属于母公司所有者权益	555,566,666	542,076,420	2.5%
归属于母公司所有者权益合计	555,566,666	542,076,420	2.5%

Note 1: 本集团于2021年3月31日的所有者权益中，归属于母公司的所有者权益为555,566,666元，较2020年12月31日的542,076,420元增加了2.5%。其中，未分配利润增加了6.5%。本集团在报告期内不存在其他所有者权益变动事项。

Note 2: 本集团于2021年3月31日的总资产为1,123,456,789元，较2020年12月31日的1,098,765,432元增加了2.3%。其中，流动资产增加了2.5%，非流动资产增加了1.9%。本集团在报告期内不存在其他资产变动事项。

1. *Handwritten text in Hindi*

2. *Handwritten text in Hindi*

Items	Jan - Mar 2021
<i>Handwritten item description</i>	<i>Handwritten value</i>
<i>Handwritten item description (continued)</i>	<i>Handwritten value</i>
<i>Handwritten item description</i>	<i>Handwritten value</i>
<i>Handwritten item description</i>	<i>Handwritten value</i>
<i>Handwritten item description</i>	<i>Handwritten value</i>
<i>Handwritten item description (continued)</i>	<i>Handwritten value</i>
<i>Handwritten item description</i>	<i>Handwritten value</i>
<i>Handwritten item description</i>	<i>Handwritten value</i>

3. *Handwritten text in Hindi*

4. *Handwritten text in Hindi*

Handwritten text in Hindi

Handwritten text in Hindi

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	111,211,111.11	111,111,111.11	100.00%	Revenue increased due to the expansion of business scope and the increase in sales volume.
Cost of sales	66,666,666.67	66,666,666.67	100.00%	Cost of sales increased due to the increase in sales volume and the increase in unit cost.
Operating expenses	22,222,222.22	22,222,222.22	100.00%	Operating expenses increased due to the increase in sales volume and the increase in unit cost.
Operating income	22,322,222.22	22,222,222.22	100.00%	Operating income increased due to the increase in sales volume and the increase in unit cost.
Other income	11,111,111.11	11,111,111.11	100.00%	Other income increased due to the increase in sales volume and the increase in unit cost.
Other expenses	11,111,111.11	11,111,111.11	100.00%	Other expenses increased due to the increase in sales volume and the increase in unit cost.
Profit before tax	33,333,333.33	33,333,333.33	100.00%	Profit before tax increased due to the increase in sales volume and the increase in unit cost.
Income tax expense	11,111,111.11	11,111,111.11	100.00%	Income tax expense increased due to the increase in sales volume and the increase in unit cost.
Net income	22,222,222.22	22,222,222.22	100.00%	Net income increased due to the increase in sales volume and the increase in unit cost.

()

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 本公司擬在境外發行總額為人民幣1,111,111,111元的非公開定向發行 (Non-public Offering) ...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2021年12月31日... %

... () ...
(16 Fosun Pharma 01)-

... S S

2021 Restricted Share Incentive Scheme

... S %
... S S %
... %

... S S

...

...

...

...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

...

* for identification purposes only

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other current assets	567,890,123	545,678,901
Non-current assets:		
Property, plant and equipment	345,678,901	323,456,789
Intangible assets	123,456,789	112,345,678
Investments	234,567,890	212,345,678
Other non-current assets	567,890,123	545,678,901
Current liabilities:		
Accounts payable	123,456,789	112,345,678
Other current liabilities	234,567,890	212,345,678
Non-current liabilities:		
Long-term debt	345,678,901	323,456,789
Other non-current liabilities	123,456,789	112,345,678

Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term debt	1,234,567,890.12	1,123,456,789.01
Deferred income tax liabilities	123,456,789.01	134,567,890.12
Other non-current liabilities	567,890,123.45	678,901,234.56
Total non-current liabilities	1,925,914,802.58	1,937,325,913.69
Equity:		
Paid-up capital	1,000,000,000.00	1,000,000,000.00
Reserves	800,000,000.00	750,000,000.00
Other equity	100,000,000.00	100,000,000.00
Total equity	1,900,000,000.00	1,850,000,000.00
Total	3,825,914,802.58	3,787,325,913.69

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111,111	1,111,111,111
二、营业成本	(666,666,666)	(666,666,666)
三、营业利润	444,444,445	444,444,445
四、营业外收入	111,111,111	111,111,111
五、营业外支出	(55,555,555)	(55,555,555)
六、利润总额	500,000,001	500,000,001
七、所得税费用	(111,111,111)	(111,111,111)
八、净利润	388,888,890	388,888,890
九、其他综合收益	111,111,111	111,111,111
十、综合收益总额	500,000,001	500,000,001
十一、归属于母公司所有者的综合收益总额	388,888,890	388,888,890
十二、归属于少数股东的综合收益总额	111,111,111	111,111,111
十三、每股收益	1.11	1.11
十四、每股其他综合收益	0.11	0.11

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,144,771,771	1,111,111,771
二、营业成本	(600,000,000)	(600,000,000)
三、营业利润	544,771,771	511,111,771
四、利润总额	544,771,771	511,111,771
五、净利润	400,000,000	400,000,000
六、其他综合收益	(100,000,000)	(100,000,000)
七、综合收益总额	300,000,000	300,000,000
八、每股收益	0.10	0.10
九、其他	(100,000,000)	(100,000,000)
十、其他	(100,000,000)	(100,000,000)
十一、其他	(100,000,000)	(100,000,000)
十二、其他	(100,000,000)	(100,000,000)
十三、其他	(100,000,000)	(100,000,000)
十四、其他	(100,000,000)	(100,000,000)
十五、其他	(100,000,000)	(100,000,000)
十六、其他	(100,000,000)	(100,000,000)
十七、其他	(100,000,000)	(100,000,000)
十八、其他	(100,000,000)	(100,000,000)
十九、其他	(100,000,000)	(100,000,000)
二十、其他	(100,000,000)	(100,000,000)
二十一、其他	(100,000,000)	(100,000,000)
二十二、其他	(100,000,000)	(100,000,000)
二十三、其他	(100,000,000)	(100,000,000)
二十四、其他	(100,000,000)	(100,000,000)
二十五、其他	(100,000,000)	(100,000,000)
二十六、其他	(100,000,000)	(100,000,000)
二十七、其他	(100,000,000)	(100,000,000)
二十八、其他	(100,000,000)	(100,000,000)
二十九、其他	(100,000,000)	(100,000,000)
三十、其他	(100,000,000)	(100,000,000)
三十一、其他	(100,000,000)	(100,000,000)
三十二、其他	(100,000,000)	(100,000,000)
三十三、其他	(100,000,000)	(100,000,000)
三十四、其他	(100,000,000)	(100,000,000)
三十五、其他	(100,000,000)	(100,000,000)
三十六、其他	(100,000,000)	(100,000,000)
三十七、其他	(100,000,000)	(100,000,000)
三十八、其他	(100,000,000)	(100,000,000)
三十九、其他	(100,000,000)	(100,000,000)
四十、其他	(100,000,000)	(100,000,000)
四十一、其他	(100,000,000)	(100,000,000)
四十二、其他	(100,000,000)	(100,000,000)
四十三、其他	(100,000,000)	(100,000,000)
四十四、其他	(100,000,000)	(100,000,000)
四十五、其他	(100,000,000)	(100,000,000)
四十六、其他	(100,000,000)	(100,000,000)
四十七、其他	(100,000,000)	(100,000,000)
四十八、其他	(100,000,000)	(100,000,000)
四十九、其他	(100,000,000)	(100,000,000)
五十、其他	(100,000,000)	(100,000,000)

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
	1,117,741,722	1,222,414,774
()	1,000,000	1,000,000
()	1,000,000	1,000,000

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	1,123,456,789	987,654,321
Depreciation and amortization	234,567,890	210,987,654
Provision for doubtful accounts	123,456,789	109,876,543
Change in accounts receivable	(56,789,012)	(45,678,901)
Change in accounts payable	345,678,901	321,098,765
Change in prepayments	(12,345,678)	(10,987,654)
Change in other assets and liabilities	(89,012,345)	(78,901,234)
Income tax expense	456,789,012	432,109,876
Change in cash and cash equivalents	1,004,234,567	876,543,210
II. Cash flow generated from investing activities:		
Capital expenditures	(123,456,789)	(109,876,543)
Acquisition of intangible assets	(45,678,901)	(34,567,890)
Disposal of fixed assets	234,567,890	210,987,654
Disposal of intangible assets	123,456,789	109,876,543
Change in other assets and liabilities	(78,901,234)	(67,890,123)
Change in cash and cash equivalents	(169,812,345)	(151,460,761)

